Video Series

A comprehensive look into MS treatment objectives is provided.

Panelists provide their closing thoughts on optimizing the management of HIV.

The panel of experts discusses emerging and anticipated changes to the HIV treatment landscape.

A discussion surrounding clinical trials in multiple sclerosis is led by Dr Haumschild.

The panel expands on the role of BTK inhibitors in the MS treatment landscape.

The panel discusses unmet needs that remain in the treatment and management of HIV.

Dr Welch leads a discussion on collaborations between payers, patients, and providers to optimize the care of patients with HIV.

In their closing thoughts, the panelists provide their key takeaways regarding immunizing against RSV.

BTK inhibitor implementation for MS treatment is explored.

The panelists provide insights into the decision-making process behind switching MS treatment strategies due to lacking or failed therapies.

Key opinion leaders discuss the value of real-world evidence in the management of HIV.

Assessing the quality of an HIV treatment plan is crucial to patient prognosis.

In her closing thoughts, Dr Filer provides insights into the unmet needs in the treatment of RSV.

Discussion surrounding promotion of RSV vaccine awareness is further discussed.

The panel offers strategies for being proactive .

Dr Haumschild leads a discussion surrounding patient and provider collaboration to avoid clinical inertia in MS treatment pathways.

Frontline treatment options and the benefits of early intervention of MS are illustrated.

Medical experts discuss the significance of pill burden in the HIV treatment pathway.

The role of and indication for long-acting injectables is highlighted as a treatment approach for HIV.

Experts discuss the financial needs for RSV vaccines through a payer lens.

Financial burden associated with RSV treatment is explored by a medical expert.

Experts highlight the potential obstacles for RSV vaccines.

Key opinion leaders highlight the MS treatment landscape.

An expert panel discusses cost burden associated with the treatment of MS.

The panelists provide their final thoughts regarding disparities in women’s health.

The treatment landscape for HIV is discussed by a panel led by Dr Welch.

Key opinion leaders discuss the influence of guideline-directed therapy in the treatment of patients with HIV.

Vaccine hesitancy is a significant barrier to optimal RSV vaccine rollout.

Experts discuss strategies to prepare for the oncoming respiratory diseases season.

Dr Filer highlights the considerations for the rollout of new RSV vaccines.